Baicalin alleviated TNBS-induced colitis by reducing the release of IL-6, TNF-α, and IL-1β and increasing the level of IL-10, promoting the expression of tight-junction proteins ZO-1 and β-catenin. The gene discussed is IL1B; the disease is colitis.